Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | ||
| Net Income | -11,143 | -28,893 |
| Depreciation Amortization | 394 | 1,051 |
| Accounts payable and accrued liabilities | 105 | N/A |
| Other Working Capital | -1,483 | -10,327 |
| Other Operating Activity | 669 | 2,056 |
| Operating Cash Flow | $-11,458 | $-36,113 |
| Cash Flows From Investing Activities | ||
| Change In Deposits | 13,683 | N/A |
| PPE Investments | -28 | -768 |
| Other Investing Activity | 0 | -13,329 |
| Investing Cash Flow | $13,655 | $-14,097 |
| Cash Flows From Financing Activities | ||
| Debt Repayment | -168 | N/A |
| Common Stock Issued | 24 | N/A |
| Other Financing Activity | 0 | 11,880 |
| Financing Cash Flow | $-144 | $11,880 |
| Beginning Cash Position | 38,289 | 76,619 |
| End Cash Position | 40,342 | 38,289 |
| Net Cash Flow | $2,053 | $-38,330 |
| Free Cash Flow | ||
| Operating Cash Flow | -11,458 | -36,113 |
| Capital Expenditure | -28 | N/A |
| Free Cash Flow | -11,486 | -36,113 |